| Barbara B Waters, MD | |
|
3949 S Cobb Dr Se, Smyrna, GA 30080-6342 | |
| (770) 434-0710 | |
| Not Available |
| Full Name | Barbara B Waters |
|---|---|
| Gender | Female |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 3949 S Cobb Dr Se, Smyrna, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003896911 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 023700 (Georgia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Barbara B Waters, MD Po Box 2994, Kennesaw, GA 30156-9181 Ph: (770) 779-2171 | Barbara B Waters, MD 3949 S Cobb Dr Se, Smyrna, GA 30080-6342 Ph: (770) 434-0710 |
News Archive
he AIFPS (Physical Activity and Health Promotion) research group of the University of Valencia has carried out a study that has made it possible to develop longitudinal profiles based on real and perceived motor competence (MC), and the physical condition of boys and girls aged 4 to 9.
PPD, Inc. today announced it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China. The acquisition strengthens PPD's full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.
AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
Despite a massive global research effort, many basics of Alzheimer's disease onset remain elusive. This has hampered development of treatments effective during the earliest stages of the disease, when prevention is most likely.
› Verified 4 days ago
Amanda F Bauer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3949 S Cobb Dr Se, Smyrna, GA 30080 Phone: 770-434-0710 | |
Mr. John C Lipman, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 3670 Highlands Pkwy Se, Smyrna, GA 30082 Phone: 770-953-2600 Fax: 770-953-2602 | |
Dr. Robert Mitchell Ermentrout, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3670 Highlands Pkwy Se, Smyrna, GA 30082 Phone: 770-953-2600 Fax: 770-953-2602 | |
Kenneth J Gargan, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3949 S Cobb Dr Se, Smyrna, GA 30080 Phone: 770-434-0710 | |
Emeka S Oraka, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 3949 S Cobb Dr Se, Smyrna, GA 30080 Phone: 770-434-0710 | |
Ashford Mcallister, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3949 S Cobb Dr Se, Smyrna, GA 30080 Phone: 770-434-0710 |